MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
0.4400
+0.0248
+5.97%
After Hours: 0.4400 0 0.00% 16:02 05/09 EDT
OPEN
0.4100
PREV CLOSE
0.4152
HIGH
0.4614
LOW
0.4100
VOLUME
213.01K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
0.3816
MARKET CAP
40.68M
P/E (TTM)
-0.2977
1D
5D
1M
3M
1Y
5Y
1D
VERRICA PHARMACEUTICALS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 13, 2025
Reuters · 4d ago
Weekly Report: what happened at VRCA last week (0428-0502)?
Weekly Report · 6d ago
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
NASDAQ · 05/02 11:10
Weekly Report: what happened at VRCA last week (0421-0425)?
Weekly Report · 04/28 12:02
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/25 21:06
Verrica Pharmaceuticals Announces Resignation of Chief Legal Officer
TipRanks · 04/25 20:49
Weekly Report: what happened at VRCA last week (0414-0418)?
Weekly Report · 04/21 12:01
Weekly Report: what happened at VRCA last week (0407-0411)?
Weekly Report · 04/14 11:48
More
About VRCA
More
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Recently
Symbol
Price
%Change

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.